

experiments using live TBEV were performed in a biosafety level 3 laboratory of the Tokyo Metropolitan Institute for Neuroscience, according to standard BSL3 guidelines.

Mice: Five-week old female C57BL/6j (B6) mice (Japan SLC, Inc., Hamamatsu, Japan) were anesthetized and then intracerebrally inoculated with a range of 10^{-1} – 10^6 PFU of TBEV diluted in EMEM containing 2% FCS. Mock-infected mice were inoculated with EMEM from supernatants of BHK cells. Mice were weighed daily and observed for clinical signs such as paralysis. Morbidity was determined by the degree of continuous weight loss, as indicated by a weight ratio of below 1.00 of compared with day 0. The experimental protocols were approved by the Animal Care and Use Committee of the Tokyo Metropolitan Institute for Neuroscience.

Virus titrations: Three mice inoculated with 10^5 PFU of virus were sacrificed, and the bloods, lungs, thymuses, spleens, brains and spinal cords were removed after perfusion with cold phosphate-buffered saline (PBS) at 3 and 6 days post-infection (pi). The brains were divided into four parts: brain cortex, thalamus, cerebellum and brain stem. Tissues were kept frozen at -80°C until use. Each tissue type was homogenized in ten volumes of PBS containing 10% FCS and diluted with EMEM containing 2% FCS. Virus titers were determined by plaque-forming assays using BHK cells and were calculated as PFU/g of tissue [20].

Histopathological examinations: Mock-infected mice and mice infected with 10^5 PFU of TBEV were anesthetized and perfused with 10% phosphate-buffered formalin 8 days pi. Fixed tissues of thymus, lung, liver, kidney, spleen, small intestine, brain, spinal cord and maxilla including nasal cavity were routinely embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Immunohistochemical detection of the TBEV antigens was performed as described previously [16]. Rabbit polyclonal antibody against anti-E protein was used to detect TBEV antigens [28].

ELISA: Serum samples were collected from 3 mock-infected mice and 3 mice infected with 10^5 PFU doses at 3 and 6 days. The levels of corticosterone and tumor necrosis factor-alpha (TNF- α) in the serum were measured using competitive EIA and sandwich ELISA kits for corticosterone (Assaypro, St. Charles, MO, U.S.A.) and TNF- α (Endogen, Woburn, MA, U.S.A.) according to the manufacturer's instructions.

Statistical analysis: Analysis of variance and the Student's *t*-test were used to assess the significance of differences in the degree of weight changes, viral loads, the numbers of leukocytes, and the expression levels of cytokines in brains and sera. A *P* value of <0.05 was considered statistically significant.

RESULTS

Mortality and morbidity: Following intracerebral infection of groups of B6 mice with sequentially increasing




Fig. 1. Mortality and morbidity following intracerebral infection with the Oshima strain of TBEV in B6 mice. Five mice in each group were intracerebrally infected with increasing concentrations of virus ranging from 10^{-1} to 10^6 PFU. (A) Mortality rates were recorded for 21 days. (B) Morbidity of mice was estimated by the degree of weight loss after 21 days.

doses, mice exhibited a dose-dependent curve of mortality, and infection with more than 10^2 PFU resulted in 100% mortality (Fig. 1A). Mice began to die at 7 days pi, and most died within 10 days pi (Fig. 2A). The mean survival times were 8.8 ± 1.89 days (10^6 PFU), 7.8 ± 0.51 days (10^5 PFU), 8.0 ± 0.00 days (10^4 PFU), 10.2 ± 2.49 days (10^3 PFU) and 9.2 ± 1.88 days (10^2 PFU), with no significant differences between the challenge doses. These observations indicate that intracerebral infection induces early death in mice even after low dose challenge.

TBEV-infected mice remained asymptomatic for 4 to 5 days and then exhibited clinical signs including weight loss, slowness in movement, ataxia, piloerection and anorexia. Mice exhibited neurological signs of paralysis such as rigidity and flaccid paralysis from 7 days pi, although 33% of the dead mice did not exhibit apparent paralysis before death.

Body weight loss was the first clinical observation. Thus, we estimated the onset of disease by whether or not the weight of each mouse decreased compared with control uninfected mice. The onset of weight loss occurred at 4.8 ± 0.51 days pi (10^6 PFU), 4.8 ± 0.51 days pi (10^5 PFU), 4.4 ± 0.62 days pi (10^4 PFU), 5.6 ± 1.02 days pi (10^3 PFU) and 6.6 ± 1.31 days pi (10^2 PFU), with no significant differences




Fig. 2. Survival curves and weight changes following intracerebral infection with 10^2 to 10^6 PFU of the Oshima strain of TBEV in B6 mice (five mice in each group). (A) Survival curves were recorded for 14 days. (B) Average daily weight changes of mice infected with 10^2 to 10^6 PFU and mock-infected mice. Daily weight loss compared with weight on day 0 is represented as a ratio. Error bars represent the standard deviations ($n=5$).

between the challenge doses (Fig. 2B). These results indicate that mice died acutely within 3 to 5 days following the onset of disease. Of note, the morbidity rates were consistent with the mortality rates (Fig. 1B), as all sick mice subsequently died.

Virus replication in mice: Next, we followed the development of viral load in mice after intracerebral infection. At 3 days pi following 10^5 PFU dose challenge, the viral loads were 10^4 to 10^6 PFU/g of tissues in peripheral organs and 10^6 to 10^7 PFU/g of tissues in the CNS (Fig. 3A), suggesting that virus replication occurred almost simultaneously in peripheral and CNS organs. At day 6 pi, the viral loads in the CNS were significantly increased to 10^8 to 10^{10} PFU/g of tissue, whereas those in peripheral organs were unchanged or had decreased (Fig. 3B). There were no significant differences between the viral loads in the brain cortex, thalamus, cerebellum, brain stem and spinal cord (Fig. 3A and 3B).

These data suggest that intracerebral infection induces

acute viral replication throughout the CNS, and thus the early death observed following intracerebral infection was directly related to the severity of viral infection in the CNS.

Histopathological features of mice: We next examined the histopathological features following intracerebral infection. Corresponding to the viral load, acutely necrotic neurons and mild inflammation were observed throughout the CNS, particularly in the brain cortex (Fig. 4A), thalamus (Fig. 4B), cerebellum (Fig. 4C) and lumbar spinal cord (Fig. 4D). Furthermore, necrotic or degenerated neurons were also observed in the maxillary plexus (Fig. 4E) and intestinal plexus (Fig. 4F). All degenerated cells examined were TBEV-antigen positive (Fig. 4A–F, insets). Mock-infected mice showed no neuronal degeneration, TBEV antigens or inflammation (Fig. 3G–I).

These results strongly suggest that early death following intracerebral infection primarily results from acute neurological dysfunction throughout the CNS directly due to viral cytopathic effects, as observed in subcutaneous infection with high challenge doses [9].

Systemic levels of corticosterone and TNF- α : We previously showed that low dose subcutaneous infections resulted in increased levels of corticosterone and TNF- α in addition to the development of CNS disease. We therefore investigated the levels of corticosterone and TNF- α in the serum following intracerebral infection. The levels of corticosterone were significantly increased in the TBEV-infected mice at 6 days pi compared with the mock-infected mice (Fig. 5A), indicating that the TBEV-infected mice exhibited a severe stress response. On the other hand, the levels of TNF- α were not increased in the TBEV-infected mice compared with the mock-infected mice (Fig. 5B). Thus, increased TNF- α is not a specific response following intracerebral infection.

DISCUSSION

In this study, we demonstrated that following intracerebral infection all mice showing clinical signs of illness subsequently died and that early death resulted from the acute and widespread neuronal degeneration caused by viral cytopathic effects in the CNS. These results suggest that even low dose challenge rapidly reached a lethal level in the CNS and that CNS pathology is directly linked to the lethality; thus, the mortality rate is dose-dependent.

On the other hand, our previous studies showed that peripheral infection with the Oshima strain of TBEV caused dose-independent mortality [2, 9]. Furthermore, depending on the dose of virus administered, a proportion of the mice died either early or late, or recovered following the onset of CNS disease [9]. Early death followed high dose challenge, and clinically, these infections were acute and occurred throughout the CNS. On the other hand, late death followed low dose challenge, and the development of CNS pathology alone did not determine fatality, suggesting that mortality results from a combination of CNS pathology, systemic stress and inflammatory response [9]. These findings indi-




Fig. 3. Virus replication in peripheral organs and the CNS following intracerebral infection with 10^5 PFU of the Oshima strain of TBEV on day 3 (A) and day 6 (B). Titers per g of tissue represent the averages from three mice in peripheral organs (blood, lung, thymus and spleen) and the CNS (regions of brain cortex, thalamus, cerebellum, brain stem and spinal cord). Error bars indicate the standard errors ($n=3$).




Fig. 4. Histopathological features in the CNS and neuroplexuses following intracerebral infection with 10^5 PFU of the Oshima strain of TBEV on day 8. Inflammation was observed around small blood vessels (cuffing) and the meninges (meningitis) in the brain cortex (A), thalamus (B), lumbar spinal cord (D) and maxillary plexus (E; arrow heads). Necrotic or degenerated neurons are indicated (A to F; asterisks). Some Purkinje cells in the cerebellum showed necrosis and neuronal loss (C). Most neurons in the intestinal plexus showed degeneration (F, asterisks). TBEV antigens were detected using E-protein specific TBEV antibody (insets). Each experiment represents three mice.




Fig. 5. The levels of corticosterone (A) and TNF- α (B) in the sera of mice following intracerebral infection with 10^5 PFU of the Oshima strain of TBEV on days 3 and 5. Titers per g of tissue represent averages from three mice. The error bars indicate the standard errors ($n=3$). The p value in each graph was determined by the analysis of variance, and the significant differences between the pairs were determined by Student's t -test.

cate that the mechanism of fatal infection is fundamentally different between intracerebral and peripheral infection.

Our previous data demonstrated that increased levels of systemic corticosterone and TNF- α contribute to the mechanism of late mortality following subcutaneous infection with low doses [9]. In the present study, the systemic corticosterone levels significantly increased following intracerebral infection (Fig. 5A), indicating that a severe systemic stress response appears to be a common factor in the lethal process of both subcutaneous and intracerebral infections. On the other hand, the levels of TNF- α did not change following intracerebral infection (Fig. 5B). Furthermore, TNF- α also remained unchanged in the early days following subcutaneous infection [9], suggesting that TNF- α increases only later in the disease progression.

In human cases, death usually occurs within 5 to 7 days of the onset of neurological symptoms [4]. It is usually believed that human cases succumb to acute and critical

neuronal dysfunction following direct viral infection of the neurons. In the present study, we showed that neurons were specific target cells of TBEV infection in the CNS and that the mice likely died due to direct viral cytopathic effects throughout the CNS. Thus, early death possibly relates to the mechanism of mortality in human cases. In addition, although adequate information on the systemic stress and inflammatory response correlated with fatal cases in humans is lacking, our results indicate that systemic responses in the late phase potentially contribute to the severity and fatality of TBE in human cases. Further elucidation of the mechanism of death in the mouse model is an important priority in development of effective treatment strategies for human TBE.

ACKNOWLEDGMENT(S). We thank Kentarou Yoshii of the Graduate School of Veterinary Medicine, Hokkaido University, Hokkaido and Ayako Harashima of the Department of Pathology of the National Institute of Infectious Diseases, Tokyo, Japan. This work was supported by a KAKENHI grant [Grant-in-Aid for Young Scientists (B) (19780230)] from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and Health Grants for Research on Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour and Welfare, Japan.

REFERENCES

- Charrel, R. N., Attoui, H., Butenko, A. M., Clegg, J. C., Deubel, V., Frolova, T. V., Gould, E. A., Gritsun, T. S., Heinz, F. X., Labuda, M., Lashkevich, V. A., Loktev, V., Lundkvist, A., Lvov, D. V., Mandl, C. W., Niedrig, M., Papa, A., Petrov, V. S., Plyusnin, A., Randolph, S., Suss, J., Zlobin, V. I. and de Lamballerie, X. 2004. Tick-borne virus diseases of human interest in Europe. *Clin. Microbiol. Infect.* **10**: 1040–1055.
- Chiba, N., Iwasaki, T., Mizutani, T., Kariwa, H., Kurata, T. and Takashima, I. 1999. Pathogenicity of tick-borne encephalitis virus isolated in Hokkaido, Japan in mouse model. *Vaccine* **17**: 779–787.
- Couderc, T., Guivel-Benhassine, F., Calaora, V., Gosselin, A. S. and Blondel, B. 2002. An ex vivo murine model to study poliovirus-induced apoptosis in nerve cells. *J. Gen. Virol.* **83**: 1925–1930.
- Dumpis, U., Crook, D. and Oksi, J. 1999. Tick-borne encephalitis. *Clin. Infect. Dis.* **28**: 882–890.
- Ecker, M., Allison, S. L., Meixner, T. and Heinz, F. X. 1999. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. *J. Gen. Virol.* **80**: 179–185.
- Gelpi, E., Preusser, M., Garzuly, F., Holzmann, H., Heinz, F. X. and Budka, H. 2005. Visualization of Central European tick-borne encephalitis infection in fatal human cases. *J. Neuropathol. Exp. Neurol.* **64**: 506–512.
- Gelpi, E., Preusser, M., Laggner, U., Garzuly, F., Holzmann, H., Heinz, F. X. and Budka, H. 2006. Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. *J. Neurovirol.* **12**: 322–327.
- Hayasaka, D., Ivanov, L., Leonova, G. N., Goto, A., Yoshii, K., Mizutani, T., Kariwa, H. and Takashima, I. 2001. Distribu-

- tion and characterization of tick-borne encephalitis viruses from Siberia and far-eastern Asia. *J. Gen. Virol.* **82**: 1319–1328.
9. Hayasaka, D., Nagata, N., Fujii, Y., Hasegawa, H., Sata, T., Suzuki, R., Gould, E. A., Takashima, I. and Koike, S. 2009. Mortality following peripheral infection with tick-borne encephalitis virus results from a combination of central nervous system pathology, systemic inflammatory and stress responses. *Virology* **390**: 139–150.
 10. Holzmann, H. 2003. Diagnosis of tick-borne encephalitis. *Vaccine* **21**: S36–40.
 11. Liao, Y., Tang, Z. Y., Liu, K. D., Ye, S. L. and Huang, Z. 1997. Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA—in vitro and in vivo studies. *J. Cancer Res. Clin. Oncol.* **123**: 25–33.
 12. Lindquist, L. and Vapalahti, O. 2008. Tick-borne encephalitis. *Lancet* **371**: 1861–1871.
 13. Mandl, C. W. 2005. Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. *Virus Res.* **111**: 161–174.
 14. Mansfield, K. L., Johnson, N., Phipps, L. P., Stephenson, J. R., Fooks, A. R. and Solomon, T. 2009. Tick-borne encephalitis virus—a review of an emerging zoonosis. *J. Gen. Virol.* **90**: 1781–1794.
 15. Monath, T. P. 1986. Pathology of the flaviviruses. pp. 375–440. *In: The Togaviridae and Flaviviridae* (Schlesinger, S. and Schlesinger, M. J. eds.), Plenum Press, New York.
 16. Nagata, N., Iwata, N., Hasegawa, H., Fukushi, S., Yokoyama, M., Harashima, A., Sato, Y., Saijo, M., Morikawa, S. and Sata, T. 2007. Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. *J. Virol.* **81**: 1848–1857.
 17. Pogodina, V. V. and Savinov, A. P. 1964. Variation in the pathogenicity of viruses of the tick-borne encephalitis complex for different animal species. I. experimental infection of mice and hamsters. *Acta Virol.* **8**: 424–434.
 18. Prikhod'ko, G. G., Prikhod'ko, E. A., Cohen, J. I. and Pletnev, A. G. 2001. Infection with Langat Flavivirus or expression of the envelope protein induces apoptotic cell death. *Virology* **286**: 328–335.
 19. Ruzek, D., Salat, J., Palus, M., Gritsun, T. S., Gould, E. A., Dykova, I., Skalova, A., Jelinek, J., Kopecky, J. and Grubhofer, L. 2009. CD8+ T-cells mediate immunopathology in tick-borne encephalitis. *Virology* **384**: 1–6.
 20. Shirato, K., Miyoshi, H., Goto, A., Ako, Y., Ueki, T., Kariwa, H. and Takashima, I. 2004. Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. *J. Gen. Virol.* **85**: 3637–3645.
 21. Shrestha, B., Gottlieb, D. and Diamond, M. S. 2003. Infection and injury of neurons by West Nile encephalitis virus. *J. Virol.* **77**: 13203–13213.
 22. Sokol, F., Libikova, H. and Zemla, J. 1959. Infectious ribonucleic acid from mouse brains infected with tick-borne encephalitis virus. *Nature* **184**: 1581.
 23. Takashima, I., Morita, K., Chiba, M., Hayasaka, D., Sato, T., Takezawa, C., Igarashi, A., Kariwa, H., Yoshimatsu, K., Arikawa, J. and Hashimoto, N. 1997. A case of tick-borne encephalitis in Japan and isolation of the virus. *J. Clin. Microbiol.* **35**: 1943–1947.
 24. Takeda, T., Ito, T., Chiba, M., Takahashi, K., Niioka, T. and Takashima, I. 1998. Isolation of tick-borne encephalitis virus from *Ixodes ovatus* (*Acari: Ixodidae*) in Japan. *J. Med. Entomol.* **35**: 227–231.
 25. Takeda, T., Ito, T., Osada, M., Takahashi, K. and Takashima, I. 1999. Isolation of tick-borne encephalitis virus from wild rodents and a seroepizootologic survey in Hokkaido, Japan. *Am. J. Trop. Med. Hyg.* **60**: 287–291.
 26. Vince, V. and Grcevic, N. 1969. Development of morphological changes in experimental tick-borne meningoencephalitis induced in white mice by different virus doses. *J. Neurol. Sci.* **9**: 109–130.
 27. Wang, Y., Lobigs, M., Lee, E. and Mullbacher, A. 2003. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. *J. Virol.* **77**: 13323–13334.
 28. Yoshii, K., Konno, A., Goto, A., Nio, J., Obara, M., Ueki, T., Hayasaka, D., Mizutani, T., Kariwa, H. and Takashima, I. 2004. Single point mutation in tick-borne encephalitis virus prM protein induces a reduction of virus particle secretion. *J. Gen. Virol.* **85**: 3049–3058.

